IP Library Granted Patent US 8,629,143
Granted Patent B2
US 8,629,143 · App. 12/949,435 · Granted Jan 14, 2014

Potassium channel modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,629,143
App. No.
12/949,435
Granted
Jan 14, 2014
Kind
B2
Abstract

Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring Z 1 , R 1 , p, R 3 , and R 4 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Claims (256)

1. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein

Z 1 is a ring fused with the pyridazine ring, selected from the group consisting of benzo, cycloalkyl, and cycloalkenyl;

R 1 is an optional substituent wherein each occurrence of R 1 is independently G a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, —CN, —NO 2 , —OR a , —OC(O)R a , —OC(O)NR a R b , —NR a R b , —SR a , —S(O)R a , —S(O) 2 R a , —S(O) 2 NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —N(R a )COOR b , —N(R a )CONR a R b , —N(R a )SO 2 NR a R b , —(CR za R zb ) m —CN, —(CR za R zb ) m —NO 2 , —(CR za R zb ) m —OR a , —(CR za R zb ) m OC(O)R a , —(CR za R zb ) m —OC(O)NR a R b , —(CR za R zb ) m —SR a , —(CR za R zb ) m —S(O)R a , —(CR za R zb ) m —S(O) 2 R a , —(CR za R zb ) m —S(O) 2 NR a R b , —(CR za R zb ) m —C(O)R a , —CR za R zb ) m —C(O)OR a —(CR za R zb ) m —C(O)NR a R b , —(CR za R zb ) m NR a R b , —(CR za R zb ) m —N(R a )COOR b , —(CR za R zb ) m —(R a )CONR a R b )R a R b , —(CR za R zb ) m —N(R a )SO 2 NR a R b , or —(CR za R zb ) m -G a ;

p is 0, 1, 2, 3, or 4;

R 3 is hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, —(CR 3a R 3b ) m -G 3 a, or G 3a ;

G 3a , at each occurrence, is independently aryl, cycloalkyl, or cycloalkenyl; each of which is optionally substituted;

R 4 is alkenyl, alkynyl, haloalkyl, —(CR 4a R 4b ) n -G 4a , or alkyl which is optionally substituted with one or two groups independently selected from the group consisting of S(R 1a ), O(R 1a ) and N(R 1a ) 2 ;

each occurrence of R 1a is independently hydrogen, G a , —(CR za R zb ) m -G a , alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl;

G 4a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is optionally substituted;

G 3a and G 3a , at each occurrence, are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of G a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, —CN, —NO 2 , —OR a , —OC(O)R a , —OC(O)NR a R b , —NR a R b , —SR a , —S(O)R a , —S(O) 2 R a , —S(O) 2 NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —N(R a )COOR b , —N(R a )CONR a R b , —N(R a )SO 2 NR a R b , —(CR za R zb ) m -G a , —(CR za R zb ) m —CN, —(CR za R zb ) m —NO 2 , —(CR za R zb ) m —OR a , —(CR za R zb ) m —OC(O)R a , —(CR za R zb ) m —OC(O)NR a R b , —(CR za R zb ) m —SR a , —(CR za R zb ) m —S(O)R a , —(CR za R zb ) m —S(O) 2 R a , —(CR za R zb ) m —S(O) 2 NR a R b , —(CR za R zb ) m —C(O)R a , —(CR za R zb ) m C(O)OR a , —(CR za R zb ) m —C(O)NR a R b , —(CR za R zb ) m —NR a R b , —(CR za R zb ) m —N(R a )COOR b , —(CR za R zb ) m —N(R a )CONR a R b , and —(CR za R zb ) m —N(R a )SO 2 NR a R b ;

G a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, —CN, —NO 2 , —OR a , —OC(O)R a , —OC(O)NR a R b , —NR a R b , —SR a , —S(O)R a , —S(O) 2 R a , —S(O) 2 NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —N(R a )COOR b , —N(R a )CONR a R b , —N(R a )SO 2 NR a R b , —(CR za R zb ) m —CN, —(CR za R zb ) m —NO 2 , —(CR za R zb ) m —OR a , —(CR za R zb ) m —OC(O)R a , —(CR za R zb ) m —OC(O)NR a R b , —(CR za R zb ) m —SR a , —(CR za R zb ) m —S(O)R a , —(CR za R zb ) m —S(O) 2 R a , —(CR za R zb ) m —S(O) 2 NR a R b , —(CR za R zb ) m C(O)R a , —(CR za R zb ) m C(O)OR a , —(CR za R zb ) m —OC(O)NR a R b , —(CR za R zb ) m —NR a R b , —(CR za R zb ) m —N(R a )COOR b , —(CR za R zb ) m —N(R a )CONR a R b , and —(CR za R zb ) m —N(R a )SO 2 NR a R b ;

R za , R zb , R 3a , R 3b , R 4a , and R 4b , at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl;

R a and R b , at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; and

m and n, at each occurrence, are each independently 1, 2, 3, or 4;

with the proviso that when Z 1 is benzo, p is 0 or 4, R 1 is halogen, R 3 is G 3a , and G 3a is aryl, substituted with 1 or 2 substituents selected from the group consisting of alkyl and unsubstituted aryl, then R 4 is other than unsubstituted alkyl or haloalkyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z 1 is benzo or cycloalkyl.

3. The compound of formula (I-a) according to claim 1 or a pharmaceutically acceptable salt thereof,

wherein

R 1 , R 3 , p, and R 4 are as set forth in claim 1 .

4. The compound of formula (I-e) according to claim 1 or a pharmaceutically acceptable salt thereof

wherein

R 1 , R 3 , R 4 , and p are as set forth in claim 1 ; and

v is 1, 2, or 3; and

y is absent, a bond, —CH 2 —, or —CH 2 CH 2 —.

5. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 3 is alkyl, halogen, haloalkyl, G 3a , or —(CR 3a R 3b ) m -G 3a .

6. The compound of formula (I) according claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is unsubstituted alkyl, haloalkyl, —C(R 4a R 4b ) n -G 4a , or alkyl substituted with a —S(R 1a ) group.

7. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z 1 is benzo or cycloalkyl; and

R 4 is unsubstituted alkyl, haloalkyl, —C(R 4a R 4b ) n -G 4a , or alkyl substituted with a —S(R 1a ) group.

8. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl; and

R 4 is —C(R 4a R 4b ) n -G 4a .

9. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl;

R 4 is —C(R 4a R 4b ) n -G 4a ; and

R 3 is alkyl, halogen, haloalkyl, G 3a , or —(CR 3a R 3b ) m -G 3a .

10. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl;

R 4 is —C(R 4a R 4b ) n -G 4a ;

R 3 is alkyl, halogen, haloalkyl, G 3a , or —(CR 3a R 3b ) m -G 3a ; and

G 3a is aryl or cycloalkyl.

11. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl; and

R 4 is unsubstituted alkyl or haloalkyl.

12. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl;

R 4 is unsubstituted alkyl or haloalkyl; and

R 3 is alkyl, halogen, haloalkyl, G 3a , or —(CR 3a R 3b ) m -G 3a .

13. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl;

R 4 is unsubstituted alkyl or haloalkyl;

R 3 is alkyl, halogen, haloalkyl, G 3a , or —(CR 3a R 3b ) m -G 3a ; and

G 3a is aryl or cycloalkyl.

14. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl; and

R 4 is alkyl substituted with a —S(R 1a ) group.

15. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl;

R 4 is alkyl substituted with a —S(R 1a ) group; and

R 3 is alkyl, halogen, haloalkyl, G 3a , or —(CR 3a R 3b ) m -G 3a .

16. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Z 1 is benzo or cycloalkyl;

R 4 is alkyl substituted with a —S(R 1a ) group;

R 3 is alkyl, halogen, haloalkyl, G 3a , or —(CR 3a R 3b ) m G 3a ; and

G 3a is aryl or cycloalkyl.

17. The compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

2-(4-chlorophenyl)-N-(4-isopropyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(1-adamantyl)-N-[4-(4-bromophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[4-(4-bromophenyl)-1-oxophthalazin-2(1H)-yl]-2-(4-chlorophenyl)acetamide;

2-(4-chlorophenyl)-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(3,5-difluorophenyl)-N-(4-isopropyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(1-adamantyl)-N-(4-isopropyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(1-adamantyl)-N-(4-isopropyl-1-oxo-5,6,7,8-tetrahydro-5,8-ethanophthalazin-2(1H)-yl)acetamide;

2-(3,5-difluorophenyl)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(1-adamantyl)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

N-(5,8-difluoro-1-oxo-4-phenylphthalazin-2(1H)-yl)-2-(4-fluorophenyl)acetamide;

2-(1-adamantyl)-N-(5,8-difluoro-1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(4-chlorophenyl)-N-(5,8-difluoro-1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(1-adamantyl)-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(3,5-difluorophenyl)-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

N-(4-chloro-1-oxophthalazin-2(1H)-yl)-2-(3,5-difluorophenyl)acetamide;

2-(1-adamantyl)-N-(4-chloro-1-oxophthalazin-2(1H)-yl)acetamide;

N-(4-chloro-1-oxophthalazin-2(1H)-yl)-2-(4-chlorophenyl)acetamide;

2-(4-chlorophenyl)-N-(4-cyclopropyl-1-oxophthalazin-2(1H)-yl)acetamide;

N-(4-cyclopropyl-1-oxophthalazin-2(1H)-yl)-2-(3,5-difluorophenyl)acetamide;

2-(1-adamantyl)-N-(4-cyclopropyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(2,3-difluorophenyl)-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(4-fluorophenyl)-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(2,5-difluorophenyl)-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(4-chlorophenyl)-N-(4-methyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-[3,5-dimethyl-1-adamantyl]-N-(4-isopropyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(3,5-difluorophenyl)-N-(6-fluoro-1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(4-chlorophenyl)-N-(6-fluoro-1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(1-adamantyl)-N-(6-fluoro-1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

2-(3,5-difluorophenyl)-N-(4-methyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-[1-(4-chlorophenyl)cyclopropyl]-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-[1-(4-chlorophenyl)cyclobutyl]-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(2-naphthyl)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

3-(4-chlorophenyl)-3-methyl-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]butanamide;

2-cyclopentyl-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2,2-difluoro-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]-2-phenylacetamide;

2-cyclobutyl-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]-2-[4-(trifluoromethyl)phenyl]acetamide;

2-[4-(dimethylamino)phenyl]-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

3,3-dimethyl-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]butanamide;

2-[4-(methylsulfonyl)phenyl]-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]-3-phenylpropanamide;

N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]-2-(1-phenylcyclopropyl)acetamide;

3-methyl-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]-3-phenylbutanamide;

N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]-2-(3-thienyl)acetamide;

N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]-2-(2-thienyl)acetamide;

2-(5-chloro-2-thienyl)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(5-methyl-2-thienyl)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]-2-phenylacetamide;

(±)-2-(exo-bicyclo[2.2.1]heptan-2-yl)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(4-chloro-3-fluorophenyl)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(3-fluoroadamantan-1-yl)-N-(4-isopropyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(3-hydroxyadamantan-1-yl)-N-(4-isopropyl-1-oxophthalazin-2(1H)-yl)acetamide;

N-(4-tert-butyl-1-oxophthalazin-2(1H)-yl)-2-cyclopentylacetamide;

(±)-2-(exo-bicyclo[2.2.1]heptan-2-yl)-N-(4-tert-butyl-1-oxophthalazin-2(1H)-yl)acetamide;

N-(4-tert-butyl-1-oxophthalazin-2(1H)-yl)-3-methyl-3-phenylbutanamide;

N-(4-tert-butyl-1-oxophthalazin-2(1H)-yl)-2-(4-chlorophenyl)acetamide;

2-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yl]-N-(4-cyclobutyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-[(1S,2S,4S)-bicyclo[2.2.1]hept-5-en-2-yl]-N-(4-cyclobutyl-1-oxophthalazin-2(1H)-yl)acetamide;

(±)-2-(exo-bicyclo[2.2.1]heptan-2-yl)-N-(4-cyclobutyl-1-oxophthalazin-2(1H)-yl)acetamide;

N-(4-cyclobutyl-1-oxophthalazin-2(1H)-yl)-2-(3,5-difluorophenyl)acetamide;

2-(4-chlorophenyl)-N-(4-cyclobutyl-1-oxophthalazin-2(1H)-yl)acetamide;

(±)-2-(exo-bicyclo[2.2.1]heptan-2-yl)-N-(4-cyclopentyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(4-chlorophenyl)-N-(4-cyclopentyl-1-oxophthalazin-2(1H)-yl)acetamide;

N-(4-cyclopentyl-1-oxophthalazin-2(1H)-yl)-2-(3,5-difluorophenyl)acetamide;

(±)-2-(exo-bicyclo[2.2.1]heptan-2-yl)-N-(4-cyclohexyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(adamantan-1-yl)-N-(4-cyclohexyl-1-oxophthalazin-2(1H)-yl)acetamide;

2-(4-chlorophenyl)-N-(4-cyclohexyl-1-oxophthalazin-2(1H)-yl)acetamide;

N-(4-cyclohexyl-1-oxophthalazin-2(1H)-yl)-2-(3,5-difluorophenyl)acetamide;

(±)-4-(3-{[(exo-bicyclo[2.2.1]heptan-2-yl)acetyl]amino}-4-oxo-3,4-dihydrophthalazin-1-yl)benzoic acid;

(±)-methyl 4-(3-{[exo-bicyclo[2.2.1]hept-2-ylacetyl]amino}-4-oxo-3,4-dihydrophthalazin-1-yl)benzoate;

methyl 4-(3-{[(4-chlorophenyl)acetyl]amino}-4-oxo-3,4-dihydrophthalazin-1-yl)benzoate;

(±)-4-(3-{[exo-bicyclo[2.2.1]hept-2-ylacetyl]amino}-4-oxo-3,4-dihydrophthalazin-1-yl)-N,N-dimethylbenzamide;

3-methyl-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)-3-phenylbutanamide;

2-(2,4-dichlorophenyl)-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide;

(±)-2-(exo-bicyclo[2.2.1]heptan-2-yl)-N-[4-(4-bromophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[4-(4-bromophenyl)-1-oxophthalazin-2(1H)-yl]-3-methyl-3-phenylbutanamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(1-methylcyclopentyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-[1-(trifluoromethyl)cyclopentyl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-[(1S,2S,5R)-3,3-difluoro-6,6-dimethylbicyclo[3.1.1]hept-2-yl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-3-methyl-3-phenylbutanamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-fluoro-2-phenylacetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-phenylacetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(morpholin-4-yl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(pyridin-3-yl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(pyridin-2-yl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(3,4-dichlorophenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(3,5-dimethoxyphenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(3,5-dimethylphenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-[4-(trifluoromethyl)phenyl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-[3-(trifluoromethyl)phenyl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-[4-(dimethylamino)phenyl]acetamide;

2-(4-bromophenyl)-N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(3-chlorophenyl)-N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(4-methoxyphenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(3-methoxyphenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(4-hydroxyphenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(4-methylphenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(3-methylphenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-cyclopentylacetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-4-methylpentanamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-[4-(methylsulfonyl)phenyl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(5-chloro-2-thienyl)acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chloro-3-fluorophenyl)-N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-[(1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]acetamide;

2-(adamantan-1-yl)-N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(3,5-difluorophenyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(1-phenylcyclopentyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-phenylcyclopropanecarboxamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(2-naphthyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(1-naphthyl)acetamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-4,4,4-trifluorobutanamide;

N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-3,3,3-trifluoropropanamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(3-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[4-(3-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[4-(3-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[4-(3-chlorophenyl)-1-oxophthalazin-2(1H)-yl]-2-(3,5-difluorophenyl)acetamide;

2-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yl]-N-[4-(4-fluorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-[(1S,2S,4S)-bicyclo[2.2.1]hept-5-en-2-yl]-N-[4-(4-fluorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(4-fluorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[4-(4-fluorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(3,5-difluorophenyl)-N-[4-(4-fluorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(2,4-difluorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[4-(4-methylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(3,5-difluorophenyl)-N-[4-(4-methylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-[(1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-N-[4-(4-methylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[4-(4-methylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-(4-benzyl-1-oxophthalazin-2(1H)-yl)-2-[1-(trifluoromethyl)cyclopentyl]acetamide;

N-(4-benzyl-1-oxophthalazin-2(1H)-yl)-3-methyl-3-phenylbutanamide;

(±)—N-(4-benzyl-1-oxophthalazin-2(1H)-yl)-2-(exo-bicyclo[2.2.1]hept-2-yl)acetamide;

N-(4-benzyl-1-oxophthalazin-2(1H)-yl)-2-(4-chlorophenyl)acetamide;

N-(4-benzyl-1-oxophthalazin-2(1H)-yl)-2-(3,5-difluorophenyl)acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(4-chlorobenzyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[4-(4-chlorobenzyl)-1-oxophthalazin-2(1H)-yl]-2-(4-chlorophenyl)acetamide;

N-[4-(4-chlorobenzyl)-1-oxophthalazin-2(1H)-yl]-2-(3,5-difluorophenyl)acetamide;

2-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yl]-N-{1-oxo-4-[4-(trifluoromethyl)phenyl]phthalazin-2(1H)-yl}acetamide;

3-methyl-N-{1-oxo-4-[4-(trifluoromethyl)phenyl]phthalazin-2(1H)-yl}-3-phenylbutanamide;

2-(adamantan-1-yl)-N-{1-oxo-4-[4-(trifluoromethyl)phenyl]phthalazin-2(1H)-yl}acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-{1-oxo-4-[4-(trifluoromethyl)phenyl]phthalazin-2(1H)-yl}acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(4-methoxyphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[4-(4-methoxyphenyl)-1-oxophthalazin-2(1H)-yl]-2-(4-methylcyclohexyl)acetamide;

2-(3,5-difluorophenyl)-N-[4-(4-methoxyphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[4-(4-methoxyphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(2,5-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[4-(2,5-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[4-(2,5-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(3,5-difluorophenyl)-N-[4-(2,5-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-[(1S,2S,4S)-bicyclo[2.2.1]hept-5-en-2-yl]-N-[4-(2,4-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(2,4-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[4-(2,4-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(3,5-difluorophenyl)-N-[4-(2,4-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(3,4-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[4-(3,4-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[4-(3,4-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(3,5-difluorophenyl)-N-[4-(3,4-dimethylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[1-oxo-4-(2-phenylethyl)phthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(4-isopropylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[4-(4-isopropylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(4-chlorophenyl)-N-[4-(4-isopropylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(3,5-difluorophenyl)-N-[4-(4-isopropylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[1-oxo-4-(1-phenylcyclopropyl)phthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[4-isopropyl-1-oxo-7-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[7-bromo-4-(4-methoxyphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[6-bromo-4-(4-methoxyphenyl)-1-oxophthalazin-2(1H)-yl]acetamide;

N-[6-bromo-4-(4-methoxyphenyl)-1-oxophthalazin-2(1H)-yl]-2-(3,5-difluorophenyl)acetamide;

N-[7-bromo-4-(4-methoxyphenyl)-1-oxophthalazin-2(1H)-yl]-2-(3,5-difluorophenyl)acetamide;

N-[4-(4-chlorophenyl)-5,8-difluoro-1-oxophthalazin-2(1H)-yl]-2-(3,5-difluorophenyl)acetamide;

2-(4-chlorophenyl)-N-[4-(4-chlorophenyl)-5,8-difluoro-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-[4-(4-chlorophenyl)-5,8-difluoro-1-oxophthalazin-2(1H)-yl]acetamide;

(±)-2-(exo-bicyclo[2.2.1]hept-2-yl)-N-[4-(4-chlorophenyl)-5,8-difluoro-1-oxophthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-yl)-N-(1-oxo-4-phenyl-5,6,7,8-tetrahydrophthalazin-2(1H)-yl)acetamide;

2-(3,5-difluorophenyl)-N-(1-oxo-4-phenyl-5,6,7,8-tetrahydrophthalazin-2(1H)-yl)acetamide;

2-(4-chlorophenyl)-N-(1-oxo-4-phenyl-5,6,7,8-tetrahydrophthalazin-2(1H)-yl)acetamide;

2-(3,5-difluorophenyl)-N-(1-oxo-4-phenyl-1,5,6,7-tetrahydro-2H-cyclopenta[d]pyridazin-2-yl)acetamide;

2-(adamantan-1-yl)-N-(1-oxo-4-phenyl-1,5,6,7-tetrahydro-2H-cyclopenta[d]pyridazin-2-yl)acetamide;

2-(4-chlorophenyl)-N-(1-oxo-4-phenyl-1,5,6,7-tetrahydro-2H-cyclopenta[d]pyridazin-2-yl)acetamide;

2-(methylthio)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-ylthio)-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide;

2-(adamantan-1-ylthio)-N-(1-oxo-4-phenylphthalazin-2(1H)-yl)acetamide; and

2-(1,3-benzodioxol-5-yl)-N-[4-(4-chlorophenyl)-1-oxophthalazin-2(1H)-yl]acetamide.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers.

19. The pharmaceutical composition according to claim 18 further comprising one or more analgesic or one or more nonsteroidal anti-inflammatory drug, or a combination thereof.

20. The pharmaceutical composition according to claim 19 wherein the nonsteroidal anti-inflammatory drug is ibuprofen.

21. A method for treating pain in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, alone or in combination with one or more pharmaceutically acceptable carrier.

22. The method according to claim 21 further comprising the step of co-administering with one or more analgesics, or with one or more nonsteroidal anti-inflammatory drug, or combination thereof.

23. The method according to claim 22 wherein the nonsteroidal anti-inflammatory drug is ibuprofen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030137/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2011
From: BROWN, BRIAN S.; LI, TONGMEI; PEREZ-MEDRANO, ARTURO; PEDDI, SRIDHAR
To: ABBOTT LABORATORIES
Reel/Frame 025724/0531 →